SCIG Hizentra denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for scig hizentra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Hizentra

Aetna requires prior authorization (PA) for Hizentra as part of its utilization management program for specialty immunoglobulin products. This means the prescription cannot be filled until Aetna confirms the clinical criteria in its coverage policy are met before the drug is dispensed. A denial at the PA stage typically means either that the request was incomplete, the submitted clinical information did not address all of Aetna's required criteria, or the documentation did not demonstrate medical necessity to the reviewing clinician.

This is one of the most common and most reversible denial types — the majority of PA denials succeed on appeal when the underlying clinical case is strong and fully documented.

## Why This Denial Is Appealable

Prior authorization denials are subject to the same internal and external appeal rights as any other coverage denial. Aetna must apply its criteria consistently, and those criteria must align with the FDA-approved prescribing label and accepted medical standards. If the clinical record supports the prescribed use, a PA denial should be challenged.

## Federal Appeal Framework

• Internal appeal: File within your plan's deadline (typically 180 days). For ongoing treatment, consider requesting an expedited review given clinical urgency.
• Peer-to-peer review: Before or during the appeal, the prescribing physician can request a peer-to-peer call with Aetna's medical reviewer — this step alone reverses many PA denials.
• External review (ACA §2719 / ERISA §503): If internal appeal is denied, request IRO review within 4 months of the final denial. The IRO can override Aetna's determination.

## Documentation to Gather

1. Completed PA request checklist — review exactly what Aetna requires and confirm every item is addressed; missing one criterion is a common reason for denial. 2. Diagnosis confirmation — specialist records establishing the qualifying diagnosis, including relevant immune or functional testing. 3. Clinical severity documentation — chart notes reflecting the frequency, severity, and clinical impact of the condition. 4. Prior treatment history — records of any prior therapy, its outcomes, and the basis for the current prescribing decision. 5. Prescriber medical-necessity letter — a comprehensive letter from the treating specialist addressing each of Aetna's PA criteria point by point.

## Criteria-Mapping Strategy

Obtain Aetna's current published medical policy and PA criteria for immunoglobulin therapy. List every criterion. For each one, identify the exact chart note, test result, or specialist record that satisfies it, with dates. Submit this as a structured letter so the reviewer can verify compliance without searching through records. Include a copy of the relevant section of the FDA-approved prescribing label confirming the prescribed indication.